Educational information

Educational objectives of this symposium were to:

• Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
• Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
• Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
• To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
• Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
• Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management
• Understand the implications of new ESC guidelines for lipid management

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

Dr. Paul M Ridker, MD, MPH, is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston.

Funding

Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron

Also watch lecture: PCSK9, the short track road from discovery as drug target towards the clinic by Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France Also watch lecture: Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?, by John Kastelein, MD, AMC, Amsterdam, The Netherlands